Literature DB >> 21570613

Late relapse of germ cell tumors.

Jan Oldenburg1, Anja Lorch, Sophie D Fosså.   

Abstract

This article highlights relevant aspects of the rare late relapses of malignant germ cell tumors (MGCTs), which by definition occur at least 2 years after successful treatment. In most reports, 1% to 6% of patients with MGCT experience a late relapse. Surgery is the most important part in the treatment of late relapses. Viable MGCT or teratoma with malignant transformation may require multimodal treatment with chemotherapy, radiotherapy, and/or surgery. Salvage chemotherapy should be based on a representative biopsy. Referring patients with late relapse to high-volume institutions ensures the best chances of cure and enables multimodal treatment.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 21570613     DOI: 10.1016/j.hoc.2011.03.006

Source DB:  PubMed          Journal:  Hematol Oncol Clin North Am        ISSN: 0889-8588            Impact factor:   3.722


  3 in total

1.  [Update on first-line and relapse chemotherapy for testicular cancer].

Authors:  A Lorch; P Albers
Journal:  Urologe A       Date:  2013-11       Impact factor: 0.639

Review 2.  Treatment of relapsed/refractory germ cell tumours: an equipoise between conventional and high dose therapy.

Authors:  Sukaina Rashid; Louise Lim; Thomas Powles
Journal:  Curr Treat Options Oncol       Date:  2012-06

3.  Management of Late Relapses in Metastatic Testicular Germ Cell Tumors: Still a Challenge.

Authors:  Axel Heidenreich
Journal:  Eur Urol Open Sci       Date:  2021-06-16
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.